5766 shire SFS artwork 11. qxd 22 6 04 4:10 pm Page 12 12 Shire Pharmaceuticals Group plc Directors Report The Directors present their report on the affairs of the Group and Mr Angus Russell, Chief Financial officer the Company together with the audited consolidated financial statements for the year ended 31 December 2003.
Dr Wilson Totten, Group R&D Director Results and dividends Dr Barry Price, Senior Non-executive Director and Chairman The loss on ordinary activities before taxation of the Group was of the Remuneration Committee 298.3 million 2002: 526.8 million.
The net assets of the Group as at 31 December 2003 were 2,308.5 million 2002: 2,747.7 The Hon James Grant, Non-executive Director million.
The Directors do not recommend the payment of a dividend 2002: nil.
Mr Ronald Nordmann, Non-executive Director and Chairman of the Audit Committee Principal activity The principal activity of the Group is the marketing and research Mr Robin Buchanan, Non-executive Director and development of prescription medicines.
The Group focuses Appointed 30 July 2003 on three therapeutic areas: central nervous system, gastrointestinal and renal medicine.
Mr Rolf Stahel, Former Chief Executive Resigned 19 March 2003 Business review A review of the Groups business and important events during the Dr Francesco Bellini, Non-executive Director year and likely future developments is set out in the Chairmans Stepped down 10 May 2003 statement, the Chief Executive Ofcers review and the Financial review on pages 2 to 9.
Mr Grard Veilleux, Non-executive Director Stepped down 10 May 2003 Corporate governance The Directors are committed to business integrity and Directors interests professionalism and as an essential part of this commitment the Details of the current Directors interests in the share capital of the Board supports high standards of corporate governance.
Details Company, as shown in the register maintained in accordance with concerning the Groups arrangements relating to corporate Section 325 of the Companies Act 1985, together with details of governance and its compliance with the Combined Code in effect the share options granted to them are disclosed in the Directors for the financial year 2003 are given on pages 14 to 17 and the remuneration report on pages 18 to 29. remuneration policy contained in the Directors remuneration report is detailed on pages 18 to 29.
Re-appointment In accordance with the Companys Articles of Association, Mr Authorised and called up share capital Robin Buchanan, having been appointed as a Director by the Details of the authorised and called up share capital of the Company Board retires at the forthcoming AGM and will be proposed for as at 31 December 2003 and the changes during the year are set re-appointment.
Dr James Cavanaugh and Dr Barry Price retire out in note 23 to the consolidated financial statements.
by rotation and offer themselves for re-appointment.
Each of the Directors being proposed for re-appointment is a non-executive Market purchases of ordinary shares Director and the terms of their respective engagements are The Company was given authority at the 2003 Annual General governed by letters of appointment.
None of the non-executive Meeting AGM to make market purchases of up to 48,452,304 Directors proposed for re-election has a service contract.
of its own ordinary shares of 5p each at a maximum price per share of 105% of the middle market price.
During the year, the Interest in material contracts Company purchased and subsequently cancelled 7,592,778 Other than the related party transactions disclosed below, none ordinary shares at a cost of 31.8 million, including expenses, of the current Directors had a material interest in any contract with a nominal value of 379,639 at prices between 398.95p of signicance to which the Company or any of its subsidiary and 441.23p, representing approximately 1.6% of its issued undertakings was a party during the period under review.
The authority will expire at the 2004 AGM and approval will be sought from shareholders at the 2004 AGM Related party transactions to renew the authority for a further year.
a The Group incurred professional fees with a Canadian law rm in which The Hon James Grant is a partner, totalling Research and development 0.5 million for the year ended 31 December 2003 2002: The Group continues an active research and development 771.
At 31 December 2003, 0.3 million 2002: nil was programme and as a result has incurred research and development due to the law rm in which the Hon James Grant is a partner.
costs of 131.7 million in the financial year ended 31 December 2003 2002: 126.1 million.
These costs have been charged to b BioChem Immunosystems Inc. Immunosystems, formerly a the consolidated profit and loss account in accordance with the wholly owned subsidiary of BioChem Pharma Inc. BioChem, Groups accounting policy.
was sold in February 2000 to a third party.
Dr Bellini, the former chief executive officer of BioChem, continued as Directors a director of Immunosystems.
In December 2001, the The Directors who served during the year were as follows: Company acquired a 19.9% equity interest in Immunosystems Dr James Cavanaugh, Chairman, Non-executive Director in consideration for the release of a debt owing to the Company and Chairman of Nomination Committee from Immunosystems.
This debt existed prior to the Companys merger with BioChem.
As part of the same Mr Matthew Emmens, Chief Executive officer transaction, the Company was released from a pre-existing Appointed 12 March 2003 BioChem guarantee over other Immunosystems liabilities.
5766 shire SFS artwork 11. qxd 22 6 04 4:10 pm Page 13 Shire Pharmaceuticals Group plc Directors Report 13 c Mr Spitznagel, a former Director of the Company, entered The Groups employment polices are developed to reect local into a consultancy agreement with the Company in legal, cultural and employment requirements and to maintain high December 1999, which provided that: standards wherever the Group operates.
Employees at all levels within the Group are encouraged to make the best possible i. Mr Spitznagel would provide consultancy services to the contribution to the Groups success.
Company for at least 42 months following the acquisition of Roberts, unless Mr Spitznagel terminated the consultancy Equal opportunities agreement prior to the end of the 42nd month upon 30 The Group operates an equal opportunities policy that aims to days notice: and treat individuals fairly and not to discriminate on grounds of sex, race, ethnic origin or disability.
The Company would pay Mr Spitznagel at a rate of including those by disabled persons, are fully considered on their 248,000 per annum for his consulting services, 93,000 merits, and employees are given appropriate training and equal per annum as an ofce allowance, 155,000 per annum to opportunities for career development and promotion.
comply with certain restrictive covenants contained therein and 93,000 per annum for tax, financial and estate Disabled employees planning advice, life insurance and health insurance.
Applications for employment by disabled persons are always fully considered, bearing in mind the aptitudes of the applicant Mr Spitznagel was paid 0.3 million for the year ended 31 concerned.
In the event of members of staff becoming disabled, December 2003 2002: 0.3 million.
The consultancy agreement every effort is made to ensure that their employment with the terminated with effect from October 2003 and no further amounts Group continues and that appropriate training is arranged.
It is are to be paid to Mr Spitznagel.
the policy of the Group that the training, career development and promotion of disabled persons should, as far as possible, Directors and Ofcers liability insurance be identical to that of other employees.
In the year under review, the Company and the Group maintained an insurance policy for its Directors and Ofcers in respect of Health, safety and welfare liabilities arising out of any act, error or omission whilst acting The Directors are committed to ensuring the health, safety and in their capacity as Directors or Ofcers.
welfare of the Groups employees at work.
Accordingly, it is the Groups policy to manage its activities so as to avoid causing any Substantial shareholdings unnecessary or unacceptable risk to employees and those who The information disclosed to the Company pursuant to sections may be affected by the Groups business.
198 to 208 of the Companies Act 1985 regarding holdings in the ordinary share capital of the Company exceeding 3% as at 10 Payment of creditors March 2004 shows that Franklin Resources, Inc. including its It is the Groups policy to agree payment terms with its suppliers, afliates have a holding of 13.94%: FMR Corp. and its direct making sure the supplier is aware of those terms, and to abide by and indirect subsidiaries and Fidelity International Limited and them.
As at 31 December 2003 there were 12 trade creditors days its direct and indirect subsidiaries collectively have a holding of outstanding 2002: 21 days.
13.05%: and the Legal & General Group has a holding of 3.04%.
Annual General Meeting Political donations The Notice convening the Annual General Meeting to be held on The Group did not make any donations to political parties during 16 June 2004 can be found in a separate notice accompanying the year ended 31 December 2003 2002: nil.
Charitable contributions Auditors During the year, UK charitable contributions amounting to On 1 August 2003, Deloitte & Touche, the Companys auditors 22,000 2002: 10,000 were made.
The contributions were transferred their entire business to Deloitte & Touche LLP, a primarily to charitable medical foundations.
limited liability partnership incorporated under the Limited Liability Partnerships Act 2000.
The Companys consent has been given Employee involvement to treating the appointment of Deloitte & Touche as extending As at 31 December 2003, the Group employed 1,815 personnel, to Deloitte & Touche LLP with effect from 1 August 2003 under 310 of whom were based in the UK.
the provisions of section 26 5 of the Companies Act 1989.
Accordingly the accounts have been signed in the name of The Group places considerable value on the involvement of Deloitte & Touche LLP.
its employees and constantly seeks to develop employee involvement throughout the Group.
Employees are kept informed A resolution proposing the re-appointment of Deloitte & Touche on matters affecting the Groups performance and on matters that LLP as auditors to the Company will be put to the Annual General concern them as employees.
The Group communicates with its Meeting in accordance with Section 384 of the Companies Act employees by routinely circulating details and announcements 1985.
The Audit Committee reviews both the level of the audit concerning the Groups performance, informing them of policies fee and the level and nature of non-audit fees as part of its review and guidelines that may affect them, and holding regular brieng of the adequacy and objectivity of the audit process.
The Group publishes an employee newsletter and information brochure to which employees have an opportunity By order of the Board to contribute.
The Group also operates various employee share schemes, details of which are set out in the Directors Tatjana May remuneration report on pages 18 to 29 and in note 23 to Company Secretary the consolidated financial statements.
